GDF15 and hydrops fetalis: A phase 2 randomized clinical trial is actively assessing ponsegromab, a monoclonal anti-GDF15-neutralizing antibody (NCT05492500), and its efficacy in treating HF in patients who exhibited upregulated levels of GDF15.